Corporate Presentation

The Exicure Difference PLATFORM Better Uptake, Greater Stability 3-D architecture drives better uptake and greater stability Preclinically demonstrated local delivery in CNS, eye, Gl tract, liver, lung, skin Mechanism-agnostic: antisense, siRNA, TLR9 modulation, splice-switching THERAPEUTICS Growing Development Pipeline RARE DISEASE FORMS NEURO Friedreich's Ataxia SCN9A- Neuropathic Pain CLN3- Battens Disease PARTNERSHIPS IMMUNO- ONCOLOGY CAVRO Phase 2- MCC, CSCC, Melanoma DERMATOLOGY abbvie Allergan + DERMELIX BIOTHERAPEUTICS Potential for additional partners VALUE XCUR (NASDAQ) MARKET CAP ~$190M 2/1/21 CASH $94M 9/30/20 POTENTIAL MILESTONE PAYMENTS AbbVie/Allergan up to $725M (2 programs underway) Dermelix up to $166M/program (up to 6 programs) CASH RUNWAY INTO 2022 exicure | 3

View entire presentation